Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells.

Huntington's disease (HD) is characterized by a late clinical onset despite ubiquitous expression of the mutant gene at all developmental stages. How mutant huntingtin impacts on signalling pathways in the pre-symptomatic period has remained essentially unexplored in humans due to a lack of appropriate models. Using multiple human embryonic stem cell lines derived from blastocysts diagnosed as carrying the mutant huntingtin gene by pre-implantation genetic diagnosis, we explored early developmental changes in gene expression using differential transcriptomics, combined with gain and loss of function strategies. We demonstrated a down-regulation of the HTT gene itself in HD neural cells and identified three genes, the expression of which differs significantly in HD cells when compared with wild-type controls, namely CHCHD2, TRIM4 and PKIB. Similar dysregulation had been observed previously for CHCDH2 and TRIM4 in blood cells from patients. CHCHD2 is involved in mitochondrial function and PKIB in protein kinase A-dependent pathway regulation, which suggests that these functions may be precociously impacted in HD.

[1]  S. Dunnett,et al.  Longitudinal analysis of gene expression and behaviour in the HdhQ150 mouse model of Huntington's disease , 2012, Brain Research Bulletin.

[2]  Lin Du,et al.  Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets , 2011, Nature Medicine.

[3]  John R. Yates,et al.  Sirt1 mediates neuroprotection from mutant huntingtin by activation of TORC1 and CREB transcriptional pathway , 2011, Nature Medicine.

[4]  M. Peschanski,et al.  Human pluripotent stem cells for disease modelling and drug screening. , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[5]  R. Faull,et al.  Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain , 2011, Nature Methods.

[6]  M. MacDonald,et al.  HD CAG-correlated gene expression changes support a simple dominant gain of function. , 2011, Human molecular genetics.

[7]  D. Kiel,et al.  Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest a Key Role in Ageing Mechanisms , 2011, PLoS genetics.

[8]  Martin Posch,et al.  Cross-platform comparison of microarray data using order restricted inference , 2011, Bioinform..

[9]  U. Schmidt,et al.  Derivation of Huntington's disease-affected human embryonic stem cell lines. , 2011, Stem cells and development.

[10]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[11]  Jinqiu Zhang,et al.  A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. , 2011, Cell stem cell.

[12]  M. Beal,et al.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. , 2010, Human molecular genetics.

[13]  Yohanns Bellaiche,et al.  Huntingtin Is Required for Mitotic Spindle Orientation and Mammalian Neurogenesis , 2010, Neuron.

[14]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[15]  M. Hayden,et al.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. , 2010, Human molecular genetics.

[16]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[17]  M. Peschanski,et al.  High-efficiency derivation of human embryonic stem cell lines following pre-implantation genetic diagnosis , 2010, In Vitro Cellular & Developmental Biology - Animal.

[18]  K. Suk,et al.  Identification of novel cell migration‐promoting genes by a functional genetic screen , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  N. Déglon,et al.  Mitochondria in Huntington's disease. , 2010, Biochimica et biophysica acta.

[20]  M. Beal,et al.  Impaired PGC-1alpha function in muscle in Huntington's disease. , 2009, Human molecular genetics.

[21]  A. Viale,et al.  Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs , 2009, Nature.

[22]  T. Gu,et al.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198‐FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide‐specific MS , 2009, Proteomics.

[23]  Roland Nilsson,et al.  A Computational Screen for Regulators of Oxidative Phosphorylation Implicates SLIRP in Mitochondrial RNA Homeostasis , 2009, PLoS genetics.

[24]  Ling Liu,et al.  Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti‐aging and metabolic effects of sirtuins , 2009, Proteomics.

[25]  M. Tomishima,et al.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.

[26]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[27]  Beate Sick,et al.  Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry , 2008, The Journal of Neuroscience.

[28]  Hyman M. Schipper,et al.  Transcriptional profiling of Alzheimer blood mononuclear cells by microarray , 2007, Neurobiology of Aging.

[29]  J. Cha,et al.  Transcriptional signatures in Huntington's disease , 2007, Progress in Neurobiology.

[30]  Mauro Delorenzi,et al.  Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood , 2007, Proceedings of the National Academy of Sciences.

[31]  Mauro Delorenzi,et al.  Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.

[32]  N. Déglon,et al.  Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Olson,et al.  Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.

[34]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[35]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[36]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[37]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[38]  P. Devroey,et al.  Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. , 2006, Human reproduction.

[39]  Katalin Illes,et al.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. , 2006, Human molecular genetics.

[40]  S. Rechitsky,et al.  Preimplantation genetic diagnosis as a source of human embryonic stem cell lines with genetic disorders , 2008 .

[41]  R V Jensen,et al.  Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Dürr,et al.  Akt is altered in an animal model of Huntington's disease and in patients , 2005, The European journal of neuroscience.

[43]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[44]  Karen Marder,et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Rubinsztein,et al.  Decreased cAMP Response Element-mediated Transcription , 2004, Journal of Biological Chemistry.

[46]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[47]  P. Puigserver,et al.  Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.

[48]  D. Rubinsztein,et al.  Modulation of polyglutamine-induced cell death by genes identified by expression profiling. , 2002, Human molecular genetics.

[49]  Christopher A. Ross,et al.  Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.

[50]  Long Yu,et al.  Protein inhibitor of neuronal nitric oxide synthase interacts with protein kinase A inhibitors. , 2002, Brain research. Molecular brain research.

[51]  D. Rubinsztein,et al.  Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.

[52]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[53]  R. Carraway,et al.  Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.